Good Faith Exam Requirements for Tirzepatide Clinics

Tirzepatide clinics can move patients into treatment quickly, but speed creates a documentation gap when the chart contains an intake form without showing who evaluated the patient, why the medication was selected, or whether approval came before prescribing. If a licensing board, pharmacy, or payer reviews the record, those missing decisions can make the prescription difficult to defend.

This guide explains the good faith exam requirements for tirzepatide clinics, including provider authority, telehealth, documentation, refill review, and differences from semaglutide. It also connects current clinical trial data with the information a defensible exam record should capture.

Good Faith Exam Requirements for Tirzepatide Clinics, Line by Line

The good faith exam requirements for tirzepatide clinics should help reviewers reconstruct the decision. The FDA’s approval of Zepbound for chronic weight management can guide the clinical template.

These tirzepatide good faith exam requirements convert patient data into a visible clinical decision.

Where a Tirzepatide Exam Stops Being a Formality

A good faith exam before tirzepatide prescription should resolve four issues that a generic GLP-1 intake may miss:

1. Current sourcing context: Tirzepatide is not currently on the FDA drug shortage list. A clinic should not assume that routine copies qualify for a shortage-based compounding pathway.
2. Product and indication: Zepbound has weight-management indications. Mounjaro is labeled for type 2 diabetes, so using it solely for weight loss is off-label and requires a documented rationale and informed discussion.
3. Drug-specific risk review: The record should separate formal contraindications from warnings, precautions, pregnancy considerations, medication effects, and symptoms that may change the plan.
4. Plan ownership: Starting dose, escalation, monitoring, and follow-up should appear in the authorized prescribing plan, not in a refill note created after treatment begins.

Clinics standardizing several medications should connect this record to their broader GLP-1 clinic compliance process.

Tirzepatide vs Semaglutide: Same Framework, Different Record

Both drugs require individualized evaluation, but their product-specific records are not interchangeable.

The difference is the evidence needed to support the product selected. Review the semaglutide exam requirements before reusing one template for both medications.

Who Can Actually Sign Off on a Tirzepatide Exam?

The professional completing the GFE before prescribing tirzepatide must be authorized to evaluate, diagnose, and prescribe under the law of the state where the patient is physically located.

• An MD or DO may evaluate and prescribe when properly licensed.
• An NP or PA may do so when state scope, collaboration, supervision, and prescribing rules permit.
• An RN may collect history, measurements, and other intake information but cannot independently diagnose, prescribe, or create the treatment order.

Tirzepatide is not a controlled substance, but that does not remove licensing, patient-provider relationship, standard-of-care, documentation, or clinic credentialing duties. Use current Endocrine Society obesity guidelines and product labeling to support clinical protocols. Confirm who can perform the exam under each state’s professional-practice rules.

Can You Run a Telehealth Good Faith Exam for Tirzepatide?

A telehealth good faith exam for tirzepatide may be permitted when state law allows remote evaluation and the encounter meets the same applicable standard of care. The provider must hold the required authority in the state where the patient is located, not merely where the clinic or provider is based.

A defensible telehealth note should identify the provider, confirm the patient’s location, describe the examination method, record relevant findings, and connect the assessment to the plan. Live, synchronous video is the stronger general model when rules require an examination capable of establishing the relationship and supporting clinical judgment. 

Asynchronous questionnaires alone create more risk because they may collect data without demonstrating a sufficient provider evaluation. Verify the medical, nursing, pharmacy, telehealth, and prescribing rules that apply to each patient encounter.

Does Every Refill Need a New Exam?

Not every tirzepatide refill automatically requires a new full GFE, but every refill requires appropriate clinical oversight. The initial evaluation must occur before the first prescription. Follow-up documentation should address response, tolerability, adherence, adverse effects, dose decisions, new medications, and changes in risk.

Repeat or expand the evaluation when:

• The diagnosis, medication, dose strategy, or treatment plan changes materially.
• The patient’s health, medication list, pregnancy status, or risk profile changes.
• The original evaluation is too old or incomplete to support the current decision.

Many clinics use periodic reassessment, often at least annually, but that interval is not a universal statute. State rules, prescriber judgment, payer requirements, and clinic policy may require earlier review. A refill cadence should be defined in the original treatment plan instead of improvised after a prescription request arrives.

Building Tirzepatide GFE Compliance That Holds Up Under Review

Weak tirzepatide GFE compliance usually becomes visible in the chart first. Common failure patterns include:

• Blanket standing orders used in place of patient-specific evaluation and prescribing.
• RN-led “exams” with no authorized prescriber making and documenting the decision.
• Cookie-cutter forms that capture answers but show no assessment or clinical rationale.
• Off-label Mounjaro use for weight loss without the indication, rationale, and consent documented.
• Prescriptions issued before the encounter note, treatment plan, or consent is completed.
• Multi-location workflows that cannot show which provider reviewed which patient.

A routed, licensed-provider process can make medical weight-loss evaluations more consistent without replacing independent judgment. GoodFaithExams.com routes structured intake to a licensed provider so the clinical decision can be evaluated and documented before treatment. The process is designed to support clearer records, not replace legal counsel, state-law review, or medical director responsibilities.

The Bottom Line for Tirzepatide Clinics

The good faith exam requirements for tirzepatide clinics are ultimately tested through the record. A board or reviewer should be able to identify the provider, patient-specific screening, chosen product and indication, clinical rationale, decision timing, and follow-up plan. That is the difference between a completed intake and a defensible pre-prescription evaluation. See how provider-reviewed tirzepatide exams are routed to a licensed provider and documented before treatment.

Frequently Asked Questions

Is a Good Faith Exam required before prescribing tirzepatide?

If a clinic asks, “is a good faith exam required for tirzepatide,” an authorized provider must complete and document an appropriate pre-prescription evaluation. Good faith exam requirements for tirzepatide clinics may use different terms by state, so verify the rules where the patient is located.

What does a provider evaluate during a tirzepatide Good Faith Exam?

The tirzepatide good faith exam requirements include indication, BMI, history, medications, risks, relevant findings, rationale, consent, and the treatment plan. The note should connect those findings to product, dose, monitoring, and follow-up decisions.

Who can legally prescribe tirzepatide and perform the GFE?

An MD, DO, NP, or PA may complete the GFE before prescribing tirzepatide when licensed and authorized in the patient’s state. NP and PA independence, collaboration, supervision, and prescriptive authority vary by jurisdiction.

Can a tirzepatide GFE be conducted via telehealth?

A telehealth good faith exam for tirzepatide may be valid when state law permits remote evaluation and the encounter meets the applicable standard of care. The note should document provider authority, patient location, examination method, findings, assessment, and plan.

How does a tirzepatide GFE differ from a semaglutide GFE?

The relationship and evaluation framework may be similar, but the record must match the medication selected. A tirzepatide note should identify the product and indication and document its specific risk review, medication considerations, titration, monitoring, and follow-up plan.

What contraindications should a provider check before tirzepatide?

Current Zepbound labeling identifies a personal or family history of medullary thyroid carcinoma, MEN 2, and serious hypersensitivity to tirzepatide or its excipients as contraindications. Providers should separately assess label warnings, pregnancy, current medications, and other patient-specific risks before prescribing.

Is a GFE required for each tirzepatide prescription refill?

Not necessarily. A new or expanded evaluation is commonly needed when the patient’s health or treatment changes materially or when the original assessment no longer supports the current prescribing decision.

What documentation must a tirzepatide clinic retain after a GFE?

The record should include the intake, encounter note, relevant findings, assessment, clinical rationale, treatment and titration plan, consent, provider identity and signature, patient location, and decision chronology. Retention periods and required elements vary by state and record type.

What happens if a clinic prescribes tirzepatide without a GFE?

Skipping the good faith exam before tirzepatide prescription may leave no defensible prescribing basis. Depending on the facts and jurisdiction, consequences may include board scrutiny, discipline, liability, pharmacy or payer problems, and corrective action.

Can a nurse practitioner perform a tirzepatide GFE independently?

Sometimes. An NP may evaluate and prescribe independently only when the state’s scope-of-practice and prescribing laws permit it, while other states require collaboration, supervision, protocols, or additional credentials.

What state laws affect tirzepatide GFE requirements?

Relevant rules may include professional licensing, scope of practice, telehealth, prescribing, patient-provider relationships, delegation, corporate practice, record retention, and pharmacy requirements. Apply the rules of the state where the patient is physically located during the encounter.

How should a clinic document a patient’s weight-loss history during the GFE?

Strong tirzepatide GFE compliance documentation records previous interventions, medications, duration, response, adverse effects, weight regain, relevant comorbidities, and why tirzepatide is being considered now. A structured provider-reviewed process helps keep that history connected to the clinical decision.